Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

BACKGROUND AND OBJECTIVE: The TOWER and INO-VATE-ALL trials demonstrated the efficacy and safety of blinatumomab and inotuzumab ozogamicin (inotuzumab), respectively, versus standard-of-care (SOC) chemotherapy in adults with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Pharmacoeconomics
Hoofdauteurs: Delea, Thomas E., Zhang, Xinke, Amdahl, Jordan, Boyko, Diana, Dirnberger, Franziska, Campioni, Marco, Cong, Ze
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer International Publishing 2019
Onderwerpen:
Original Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6830399/
https://ncbi.nlm.nih.gov/pubmed/31218655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-019-00812-6
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items